Responsive image

Common name


N-ethyl-3,3-dimethyl-butanamide

IUPAC name


N-ethyl-3,3-dimethyl-butanamide

SMILES


C(C)(C)(C)CC(=O)NCC

Common name


N-ethyl-3,3-dimethyl-butanamide

IUPAC name


N-ethyl-3,3-dimethyl-butanamide

SMILES


C(C)(C)(C)CC(=O)NCC

INCHI


InChI=1S/C8H17NO/c1-5-9-7(10)6-8(2,3)4/h5-6H2,1-4H3,(H,9,10)

FORMULA


C8H17NO

Responsive image

Common name


N-ethyl-3,3-dimethyl-butanamide

IUPAC name


N-ethyl-3,3-dimethyl-butanamide





Molecular weight


143.227

clogP


1.275

clogS


-2.263

Frequency


0.0003





HBond Acceptor


1

HBond Donor


1

Total Polar
Surface Area


29.1

Number of Rings


0

Rotatable Bond


3

Drug ID Common name Structure CAS Compound class Therapeutic area
FDBD00923 Atazanavir Responsive image Anti-HIV Agents; Protease Inhibitors; HIV Protease Inhibitors; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; CYP3A4 Inhibitors; Combined Inhibitors of CYP3A4 and P-glycoprotein; Used in combination with other antiretroviral agents for the treatment of HIV-1 infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission.
1 , 1
FRAGNAME PDBID SIMILIRITY XSCORE SMILE HAC
1kvo_ligand_6_2047.mol2 1kvo 1 -6.99 CCCC(=O)NC(C)C 9
3ggv_ligand_5_2380.mol2 3ggv 1 -6.96 C(C(C)(C)C)C(=O)NC(C)C 11
1j1a_ligand_6_4543.mol2 1j1a 1 -6.91 CC(C)NC(=O)CCC 9
2o4k_ligand_4_455.mol2 2o4k 1 -6.83 C(C)(C)(C)CC(=O)NCC 10
3ekw_ligand_4_455.mol2 3ekw 1 -6.81 C(C)NC(=O)CC(C)(C)C 10
3eky_ligand_4_455.mol2 3eky 1 -6.80 C(C)NC(=O)CC(C)(C)C 10
3el9_ligand_4_455.mol2 3el9 1 -6.77 C(C(=O)NCC)C(C)(C)C 10
2aqu_ligand_4_455.mol2 2aqu 1 -6.76 C(C(=O)NCC)C(C)(C)C 10
3el1_ligand_4_455.mol2 3el1 1 -6.75 C(C(=O)NCC)C(C)(C)C 10
291 , 30